Merck & Co., Inc.
MRKCIK 0000310158 · Quarterly mode · latest period FY2026 (Q1) (ending 2026-03-31) · sourced from SEC EDGAR
At a glance · FY2026 (Q1)
Quality Score
DCF intrinsic value
DCF intrinsic value
two-stage Gordon modelProject MRK's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.
Trailing CAGR unavailable; default 8%
10% is a common all-equity benchmark for US large-caps
Should be ≤ long-run GDP growth (~2.5% nominal)
5-year explicit projection + perpetuity terminal
| Year | Projected FCF | Discounted PV |
|---|---|---|
| +1 | $13.35B | $12.14B |
| +2 | $14.42B | $11.91B |
| +3 | $15.57B | $11.7B |
| +4 | $16.82B | $11.49B |
| +5 | $18.16B | $11.28B |
| Terminal | $248.2B | $154.11B |
DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.
Capital allocation · trailing 4 quarters
how the company spent its cashBalance sheet · 2026-03-31
latest filed snapshotRecent performance · 8 quarters
Drill down
MRK Sankey
See Merck & Co., Inc.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.
Open SankeyMRK Charts
8 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.
Open Charts